Back to search

Peptide record

TPDB07501

Antibacterial Anticancer Antifungal Antiparasitic Toxicity standard
14 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB07501
Antibacterial Anticancer Antifungal Antiparasitic Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia Antifungipept CAFPdb dbAMP dbAMP 3.0
standard
No
A 14-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, Peptipedia, Antifungipept, and other sources, with an available 3D structural model.
Sequence
KRFKKFFKKVKKSV
Physicochemical Analysis
C88H148N24O16
ANDCEQGHILMPTWY
K
1798.29
11.93
8
0
5
+8
4.62
-1.129
41.43
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
0
0.00
1
Residue Composition
number
0
A
1
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
0
L
7
K
0
M
3
F
0
P
1
S
0
T
0
W
0
Y
2
V
Amino Acid Distribution
A: 0 R: 1 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 0 K: 7 M: 0 F: 3 P: 0 S: 1 T: 0 W: 0 Y: 0 V: 2
Chemical Descriptors
14
C88H148N24O16
1798.29
11.93
+8
4.62
-1.129
Evidence Records 45 records
Evidence 1 Activity

Activity

MIC
Antibacterial
71 µM

Target

Enterococcus faecalis ATCC 29212 and a clinical isolate

Source & Reference

dbAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class.
active against E. faecalis ATCC 29212 and a clinical isolate (MIC 71 uM), S. aureus ATCC 29213 and a clinical isolate (MIC 71 uM), S. pyogenes clinical isolate (M
Evidence 2 Activity

Activity

MIC
Antibacterial
71 µM

Target

Staphylococcus aureus ATCC 29213 and a clinical isolate

Source & Reference

dbAMP

Other

active against E. faecalis ATCC 29212 and a clinical isolate (MIC 71 uM), S. aureus ATCC 29213 and a clinical isolate (MIC 71 uM), S. pyogenes clinical isolate (MIC 36 uM), P. aeruginosa ATCC 27853 and a clinical isolat
Evidence 3 Activity

Activity

MIC
Antibacterial
36 µM

Target

Streptococcus pyogenes clinical isolate

Source & Reference

dbAMP

Other

a clinical isolate (MIC 71 uM), S. aureus ATCC 29213 and a clinical isolate (MIC 71 uM), S. pyogenes clinical isolate (MIC 36 uM), P. aeruginosa ATCC 27853 and a clinical isolate (MIC 71 uM), K. pneumoniae clinical isol
Evidence 4 Activity

Activity

MIC
Antibacterial
71 µM

Target

Pseudomonas aeruginosa ATCC 27853 and a clinical isolate

Source & Reference

dbAMP

Other

ATCC 29213 and a clinical isolate (MIC 71 uM), S. pyogenes clinical isolate (MIC 36 uM), P. aeruginosa ATCC 27853 and a clinical isolate (MIC 71 uM), K. pneumoniae clinical isolate (MIC 71 uM), E. coli ATCC 25922 and a clinical isolate (M
Evidence 5 Activity

Activity

MIC
Antibacterial
71 µM

Target

Klebsiella pneumoniae clinical isolate

Source & Reference

dbAMP

Other

linical isolate (MIC 36 uM), P. aeruginosa ATCC 27853 and a clinical isolate (MIC 71 uM), K. pneumoniae clinical isolate (MIC 71 uM), E. coli ATCC 25922 and a clinical isolate (MIC 71 uM), and A. baumannii clinical isolate
Evidence 6 Activity

Activity

MIC
Antibacterial
71 µM

Target

Escherichia coli ATCC 25922 and a clinical isolate

Source & Reference

dbAMP

Other

TCC 27853 and a clinical isolate (MIC 71 uM), K. pneumoniae clinical isolate (MIC 71 uM), E. coli ATCC 25922 and a clinical isolate (MIC 71 uM), and A. baumannii clinical isolate (MIC 71 uM). Fungi: active against yeasts C-parapsilos
Evidence 7 Activity

Activity

MIC
Antibacterial
71 µM

Target

A. baumannii clinical isolate

Source & Reference

dbAMP

Other

clinical isolate (MIC 71 uM), E. coli ATCC 25922 and a clinical isolate (MIC 71 uM), and A. baumannii clinical isolate (MIC 71 uM). Fungi: active against yeasts C-parapsilosis ATCC 22019 (MIC>40 uM), C. krusei ATCC 6258
Evidence 8 Activity

Activity

MIC
Antibacterial
40 µM

Target

C. krusei ATCC 6258

Source & Reference

dbAMP

Other

isolate (MIC 71 uM). Fungi: active against yeasts C-parapsilosis ATCC 22019 (MIC>40 uM), C. krusei ATCC 6258 (MIC 40 uM), C. tropicalis LABMIC 0109 (MIC 10-20 uM), C. albicans LABMIC 0107 or 0108 (MIC 10-40 uM)
Evidence 9 Activity

Activity

MIC
Antibacterial
10-20 µM

Target

C. tropicalis LABMIC 0109

Source & Reference

dbAMP

Other

ve against yeasts C-parapsilosis ATCC 22019 (MIC>40 uM), C. krusei ATCC 6258 (MIC 40 uM), C. tropicalis LABMIC 0109 (MIC 10-20 uM), C. albicans LABMIC 0107 or 0108 (MIC 10-40 uM), C. parapsilosis LABMIC 0113 (MIC 20 uM),
Evidence 10 Activity

Activity

MIC
Antibacterial
10-40 µM

Target

Candida albicans LABMIC 0107 or 0108

Source & Reference

dbAMP

Other

9 (MIC>40 uM), C. krusei ATCC 6258 (MIC 40 uM), C. tropicalis LABMIC 0109 (MIC 10-20 uM), C. albicans LABMIC 0107 or 0108 (MIC 10-40 uM), C. parapsilosis LABMIC 0113 (MIC 20 uM), C. laurentii LABMIC 0404 (MIC 20 uM), Dermatoph
Evidence 11 Activity

Activity

MIC
Antibacterial
20 µM

Target

C. parapsilosis LABMIC 0113

Source & Reference

dbAMP

Other

C. tropicalis LABMIC 0109 (MIC 10-20 uM), C. albicans LABMIC 0107 or 0108 (MIC 10-40 uM), C. parapsilosis LABMIC 0113 (MIC 20 uM), C. laurentii LABMIC 0404 (MIC 20 uM), Dermatophythes M. canis LABMIC 0401 (MIC 10 uM), T
Evidence 12 Activity

Activity

MIC
Antibacterial
20 µM

Target

C. laurentii LABMIC 0404

Source & Reference

dbAMP

Other

C. albicans LABMIC 0107 or 0108 (MIC 10-40 uM), C. parapsilosis LABMIC 0113 (MIC 20 uM), C. laurentii LABMIC 0404 (MIC 20 uM), Dermatophythes M. canis LABMIC 0401 (MIC 10 uM), T-rubrum LABMIC 0203 or 0204 (MIC > 40
Evidence 13 Activity

Activity

MIC
Antibacterial
10 µM

Target

M. canis LABMIC 0401

Source & Reference

dbAMP

Other

arapsilosis LABMIC 0113 (MIC 20 uM), C. laurentii LABMIC 0404 (MIC 20 uM), Dermatophythes M. canis LABMIC 0401 (MIC 10 uM), T-rubrum LABMIC 0203 or 0204 (MIC > 40 uM) ( Cavalcante et al., 2017 ).
Evidence 14 Activity

Activity

MIC
Antifungal
71 µM

Target

Enterococcus faecalis ATCC 29212 and a clinical isolate

Source & Reference

dbAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class.
active against E. faecalis ATCC 29212 and a clinical isolate (MIC 71 uM), S. aureus ATCC 29213 and a clinical isolate (MIC 71 uM), S. pyogenes clinical isolate (M
Evidence 15 Activity

Activity

MIC
Antifungal
71 µM

Target

Staphylococcus aureus ATCC 29213 and a clinical isolate

Source & Reference

dbAMP CAFPdb Antifungipept

Other

active against E. faecalis ATCC 29212 and a clinical isolate (MIC 71 uM), S. aureus ATCC 29213 and a clinical isolate (MIC 71 uM), S. pyogenes clinical isolate (MIC 36 uM), P. aeruginosa ATCC 27853 and a clinical isolat
Evidence 16 Activity

Activity

MIC
Antifungal
36 µM

Target

Streptococcus pyogenes clinical isolate

Source & Reference

dbAMP CAFPdb Antifungipept

Other

a clinical isolate (MIC 71 uM), S. aureus ATCC 29213 and a clinical isolate (MIC 71 uM), S. pyogenes clinical isolate (MIC 36 uM), P. aeruginosa ATCC 27853 and a clinical isolate (MIC 71 uM), K. pneumoniae clinical isol
Evidence 17 Activity

Activity

MIC
Antifungal
71 µM

Target

Pseudomonas aeruginosa ATCC 27853 and a clinical isolate

Source & Reference

dbAMP CAFPdb Antifungipept

Other

ATCC 29213 and a clinical isolate (MIC 71 uM), S. pyogenes clinical isolate (MIC 36 uM), P. aeruginosa ATCC 27853 and a clinical isolate (MIC 71 uM), K. pneumoniae clinical isolate (MIC 71 uM), E. coli ATCC 25922 and a clinical isolate (M
Evidence 18 Activity

Activity

MIC
Antifungal
71 µM

Target

Klebsiella pneumoniae clinical isolate

Source & Reference

dbAMP CAFPdb Antifungipept

Other

linical isolate (MIC 36 uM), P. aeruginosa ATCC 27853 and a clinical isolate (MIC 71 uM), K. pneumoniae clinical isolate (MIC 71 uM), E. coli ATCC 25922 and a clinical isolate (MIC 71 uM), and A. baumannii clinical isolate
Evidence 19 Activity

Activity

MIC
Antifungal
71 µM

Target

Escherichia coli ATCC 25922 and a clinical isolate

Source & Reference

dbAMP CAFPdb Antifungipept

Other

TCC 27853 and a clinical isolate (MIC 71 uM), K. pneumoniae clinical isolate (MIC 71 uM), E. coli ATCC 25922 and a clinical isolate (MIC 71 uM), and A. baumannii clinical isolate (MIC 71 uM). Fungi: active against yeasts C-parapsilos
Evidence 20 Activity

Activity

MIC
Antifungal
71 µM

Target

A. baumannii clinical isolate

Source & Reference

dbAMP CAFPdb Antifungipept

Other

clinical isolate (MIC 71 uM), E. coli ATCC 25922 and a clinical isolate (MIC 71 uM), and A. baumannii clinical isolate (MIC 71 uM). Fungi: active against yeasts C-parapsilosis ATCC 22019 (MIC>40 uM), C. krusei ATCC 6258
Evidence 21 Activity

Activity

MIC
Antifungal
40 µM

Target

C. krusei ATCC 6258

Source & Reference

dbAMP CAFPdb Antifungipept

Other

isolate (MIC 71 uM). Fungi: active against yeasts C-parapsilosis ATCC 22019 (MIC>40 uM), C. krusei ATCC 6258 (MIC 40 uM), C. tropicalis LABMIC 0109 (MIC 10-20 uM), C. albicans LABMIC 0107 or 0108 (MIC 10-40 uM)
Evidence 22 Activity

Activity

MIC
Antifungal
10-20 µM

Target

C. tropicalis LABMIC 0109

Source & Reference

dbAMP CAFPdb Antifungipept

Other

ve against yeasts C-parapsilosis ATCC 22019 (MIC>40 uM), C. krusei ATCC 6258 (MIC 40 uM), C. tropicalis LABMIC 0109 (MIC 10-20 uM), C. albicans LABMIC 0107 or 0108 (MIC 10-40 uM), C. parapsilosis LABMIC 0113 (MIC 20 uM),
Evidence 23 Activity

Activity

MIC
Antifungal
10-40 µM

Target

Candida albicans LABMIC 0107 or 0108

Source & Reference

dbAMP CAFPdb Antifungipept

Other

9 (MIC>40 uM), C. krusei ATCC 6258 (MIC 40 uM), C. tropicalis LABMIC 0109 (MIC 10-20 uM), C. albicans LABMIC 0107 or 0108 (MIC 10-40 uM), C. parapsilosis LABMIC 0113 (MIC 20 uM), C. laurentii LABMIC 0404 (MIC 20 uM), Dermatoph
Evidence 24 Activity

Activity

MIC
Antifungal
20 µM

Target

C. parapsilosis LABMIC 0113

Source & Reference

dbAMP CAFPdb Antifungipept

Other

C. tropicalis LABMIC 0109 (MIC 10-20 uM), C. albicans LABMIC 0107 or 0108 (MIC 10-40 uM), C. parapsilosis LABMIC 0113 (MIC 20 uM), C. laurentii LABMIC 0404 (MIC 20 uM), Dermatophythes M. canis LABMIC 0401 (MIC 10 uM), T
Evidence 25 Activity

Activity

MIC
Antifungal
20 µM

Target

C. laurentii LABMIC 0404

Source & Reference

dbAMP CAFPdb Antifungipept

Other

C. albicans LABMIC 0107 or 0108 (MIC 10-40 uM), C. parapsilosis LABMIC 0113 (MIC 20 uM), C. laurentii LABMIC 0404 (MIC 20 uM), Dermatophythes M. canis LABMIC 0401 (MIC 10 uM), T-rubrum LABMIC 0203 or 0204 (MIC > 40
Evidence 26 Activity

Activity

MIC
Antifungal
10 µM

Target

M. canis LABMIC 0401

Source & Reference

dbAMP CAFPdb Antifungipept

Other

arapsilosis LABMIC 0113 (MIC 20 uM), C. laurentii LABMIC 0404 (MIC 20 uM), Dermatophythes M. canis LABMIC 0401 (MIC 10 uM), T-rubrum LABMIC 0203 or 0204 (MIC > 40 uM) ( Cavalcante et al., 2017 ).
Evidence 27 Activity

Activity

MIC
Antiparasitic
71 µM

Target

Enterococcus faecalis ATCC 29212 and a clinical isolate

Source & Reference

dbAMP 3.0

Other

Source Activity Label Source Definition
Antiparasitic
dbAMP 3.0 classified under the Anti-parasitic function class.
active against E. faecalis ATCC 29212 and a clinical isolate (MIC 71 uM), S. aureus ATCC 29213 and a clinical isolate (MIC 71 uM), S. pyogenes clinical isolate (M
Evidence 28 Activity

Activity

MIC
Antiparasitic
71 µM

Target

Staphylococcus aureus ATCC 29213 and a clinical isolate

Source & Reference

dbAMP 3.0

Other

active against E. faecalis ATCC 29212 and a clinical isolate (MIC 71 uM), S. aureus ATCC 29213 and a clinical isolate (MIC 71 uM), S. pyogenes clinical isolate (MIC 36 uM), P. aeruginosa ATCC 27853 and a clinical isolat
Evidence 29 Activity

Activity

MIC
Antiparasitic
36 µM

Target

Streptococcus pyogenes clinical isolate

Source & Reference

dbAMP 3.0

Other

a clinical isolate (MIC 71 uM), S. aureus ATCC 29213 and a clinical isolate (MIC 71 uM), S. pyogenes clinical isolate (MIC 36 uM), P. aeruginosa ATCC 27853 and a clinical isolate (MIC 71 uM), K. pneumoniae clinical isol
Evidence 30 Activity

Activity

MIC
Antiparasitic
71 µM

Target

Pseudomonas aeruginosa ATCC 27853 and a clinical isolate

Source & Reference

dbAMP 3.0

Other

ATCC 29213 and a clinical isolate (MIC 71 uM), S. pyogenes clinical isolate (MIC 36 uM), P. aeruginosa ATCC 27853 and a clinical isolate (MIC 71 uM), K. pneumoniae clinical isolate (MIC 71 uM), E. coli ATCC 25922 and a clinical isolate (M
Evidence 31 Activity

Activity

MIC
Antiparasitic
71 µM

Target

Klebsiella pneumoniae clinical isolate

Source & Reference

dbAMP 3.0

Other

linical isolate (MIC 36 uM), P. aeruginosa ATCC 27853 and a clinical isolate (MIC 71 uM), K. pneumoniae clinical isolate (MIC 71 uM), E. coli ATCC 25922 and a clinical isolate (MIC 71 uM), and A. baumannii clinical isolate
Evidence 32 Activity

Activity

MIC
Antiparasitic
71 µM

Target

Escherichia coli ATCC 25922 and a clinical isolate

Source & Reference

dbAMP 3.0

Other

TCC 27853 and a clinical isolate (MIC 71 uM), K. pneumoniae clinical isolate (MIC 71 uM), E. coli ATCC 25922 and a clinical isolate (MIC 71 uM), and A. baumannii clinical isolate (MIC 71 uM). Fungi: active against yeasts C-parapsilos
Evidence 33 Activity

Activity

MIC
Antiparasitic
71 µM

Target

A. baumannii clinical isolate

Source & Reference

dbAMP 3.0

Other

clinical isolate (MIC 71 uM), E. coli ATCC 25922 and a clinical isolate (MIC 71 uM), and A. baumannii clinical isolate (MIC 71 uM). Fungi: active against yeasts C-parapsilosis ATCC 22019 (MIC>40 uM), C. krusei ATCC 6258
Evidence 34 Activity

Activity

MIC
Antiparasitic
40 µM

Target

C. krusei ATCC 6258

Source & Reference

dbAMP 3.0

Other

isolate (MIC 71 uM). Fungi: active against yeasts C-parapsilosis ATCC 22019 (MIC>40 uM), C. krusei ATCC 6258 (MIC 40 uM), C. tropicalis LABMIC 0109 (MIC 10-20 uM), C. albicans LABMIC 0107 or 0108 (MIC 10-40 uM)
Evidence 35 Activity

Activity

MIC
Antiparasitic
10-20 µM

Target

C. tropicalis LABMIC 0109

Source & Reference

dbAMP 3.0

Other

ve against yeasts C-parapsilosis ATCC 22019 (MIC>40 uM), C. krusei ATCC 6258 (MIC 40 uM), C. tropicalis LABMIC 0109 (MIC 10-20 uM), C. albicans LABMIC 0107 or 0108 (MIC 10-40 uM), C. parapsilosis LABMIC 0113 (MIC 20 uM),
Evidence 36 Activity

Activity

MIC
Antiparasitic
10-40 µM

Target

Candida albicans LABMIC 0107 or 0108

Source & Reference

dbAMP 3.0

Other

9 (MIC>40 uM), C. krusei ATCC 6258 (MIC 40 uM), C. tropicalis LABMIC 0109 (MIC 10-20 uM), C. albicans LABMIC 0107 or 0108 (MIC 10-40 uM), C. parapsilosis LABMIC 0113 (MIC 20 uM), C. laurentii LABMIC 0404 (MIC 20 uM), Dermatoph
Evidence 37 Activity

Activity

MIC
Antiparasitic
20 µM

Target

C. parapsilosis LABMIC 0113

Source & Reference

dbAMP 3.0

Other

C. tropicalis LABMIC 0109 (MIC 10-20 uM), C. albicans LABMIC 0107 or 0108 (MIC 10-40 uM), C. parapsilosis LABMIC 0113 (MIC 20 uM), C. laurentii LABMIC 0404 (MIC 20 uM), Dermatophythes M. canis LABMIC 0401 (MIC 10 uM), T
Evidence 38 Activity

Activity

MIC
Antiparasitic
20 µM

Target

C. laurentii LABMIC 0404

Source & Reference

dbAMP 3.0

Other

C. albicans LABMIC 0107 or 0108 (MIC 10-40 uM), C. parapsilosis LABMIC 0113 (MIC 20 uM), C. laurentii LABMIC 0404 (MIC 20 uM), Dermatophythes M. canis LABMIC 0401 (MIC 10 uM), T-rubrum LABMIC 0203 or 0204 (MIC > 40
Evidence 39 Activity

Activity

MIC
Antiparasitic
10 µM

Target

M. canis LABMIC 0401

Source & Reference

dbAMP 3.0

Other

arapsilosis LABMIC 0113 (MIC 20 uM), C. laurentii LABMIC 0404 (MIC 20 uM), Dermatophythes M. canis LABMIC 0401 (MIC 10 uM), T-rubrum LABMIC 0203 or 0204 (MIC > 40 uM) ( Cavalcante et al., 2017 ).
Evidence 40 Activity

Activity

Toxicity
Hemolytic Cytotoxic
- | NA | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Structural Dissection of Crotalicidin, a Rattlesnake Venom Cathelicidin, Retrieves a Fragment with Antimicrobial and Antitumor Activity. | J Med Chem | 2015
Evidence 41 Activity

Activity

Toxicity
Cytotoxic
- | NA | target cell: Human fibroblasts

Target

Human fibroblasts

Source & Reference

NA
DBAASP
Structural Dissection of Crotalicidin, a Rattlesnake Venom Cathelicidin, Retrieves a Fragment with Antimicrobial and Antitumor Activity. | J Med Chem | 2015
Evidence 42 Activity

Activity

EC50
Toxicity
>100 µM
Cytotoxic
EC50 | >100 | µM | target cell: Monkey kidney epithelial cells LLC-MK2

Target

Monkey kidney epithelial cells LLC-MK2

Source & Reference

NA
DBAASP
Antichagasic effect of crotalicidin, a cathelicidin-like vipericidin, found in Crotalus durissus terrificus rattlesnake's venom gland. | Parasitology | 2017
Evidence 43 Activity

Activity

0% Hemolysis
Toxicity
100 µM
Hemolytic Cytotoxic
0% Hemolysis | 100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Structural Dissection of Crotalicidin, a Rattlesnake Venom Cathelicidin, Retrieves a Fragment with Antimicrobial and Antitumor Activity. | J Med Chem | 2015
Evidence 44 Activity

Activity

7% Hemolysis
Toxicity
400 µM
Hemolytic Cytotoxic
7% Hemolysis | 400 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Structural Dissection of Crotalicidin, a Rattlesnake Venom Cathelicidin, Retrieves a Fragment with Antimicrobial and Antitumor Activity. | J Med Chem | 2015
Evidence 45 Activity

Activity

IC50
Toxicity
12.78
Hemolytic Cytotoxic
Hemolytic_activity: Human erythrocytes: nonhemolytic up to 400 µM, and their equimolar mixture at that concentration caused only 7% hemolysis | Cytotoxicity: Human Splenic Fibroblasts (HSF): IC50=12.78±0.33 µg/mL Endometrial epithelial cells(HEEC): IC50=2.66±0.34 µg/mL HPDE6c7 Human Pancreatic Duct Epithelial Cell: IC50=3.45±0.20 µg/mL Normal Human Hepatic Cell (Lo-2): IC50=2.91±0.07 µg/mL NCM460: IC50=3.04±0.10 µg/mL CCD-19Lu: IC50=4.76±0.03 µg/mL

Target

erythrocytes

Source & Reference

NA
DRAMP
J Med Chem. 2015 Nov 12 58(21):8553-63.